Pharmaceuticals News and Research

RSS

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare’s range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare’s Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.

17 Feb 2010

ECR Pharmaceuticals to promote Urocit-K 15mEq tablets to primary care physicians

Hi-Tech Pharmacal Co., Inc. announced today that its branded marketing subsidiary, ECR Pharmaceuticals will promote Urocit®-K 15mEq, potassium citrate extended release tablets to primary care physicians beginning in April, 2010. Hi-Tech has a license agreement with Mission Pharmacal Company, which will promote the product to Urologists.

17 Feb 2010

Study: Researchers use genomics to decode blueprint of Plasmodium falciparum

Scientists battling malaria have earned a major victory. According to a Nature Genetics study, an international group of researchers has used genomics to decode the blueprint of Plasmodium falciparum - a strain of malaria most resistant to drugs that causes the most deaths around the world.

17 Feb 2010

Covidien's Exalgo NDA: FDA sets new PDUFA action date

Covidien today announced that the U.S. Food and Drug Administration has set a new action date of March 1, 2010, under the Prescription Drug User Fee Act (PDUFA) for the review of the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) Extended-Release Tablets, (CII).

17 Feb 2010

Covidien, IAE POLATOM announce agreement to augment supply of Mo 99 to produce Tc 99m

Covidien, a leading global provider of healthcare products, and the Institute of Atomic Energy in Poland today announced an agreement to augment and further diversify Covidien’s supply of Molybdenum 99 (Mo 99) to produce the medical isotope Technetium 99m (Tc 99m).

17 Feb 2010

Ironwood Pharmaceuticals' IPO: Underwriters exercise over-allotment option

Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood’s Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).

17 Feb 2010

USPTO issues two new patents for EKR Therapeutics' RTU Cardene I.V. Premixed Injection

EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that the US Patent and Trademark Office has issued two new patents covering methods of treatment and methods of preparation for the Company’s Ready-to-Use (RTU) Cardene® I.V. (nicardipine hydrochloride) Premixed Injection.

17 Feb 2010

AZ&Me Prescription Savings programs help 13% more patients in 2009

AstraZeneca announced today that it provided $769.6 million in savings to 507,475 patients in the United States last year through its AZ&Me™ Prescription Savings programs.

17 Feb 2010

APCER PHARMA to demonstrate pharmacovigilance/drug safety and regulatory services at GPhA meeting

APCER PHARMA executives will discuss and demonstrate their expertise in providing generic drug manufacturers with the best in class pharmacovigilance/drug safety, regulatory and risk management services at the GPhA Annual Meeting, February 16-18, at the Ritz-Carlton in Naples, Florida. APCER will be in Booth #27.

17 Feb 2010

CMS study predicts healthcare spending may double by 2019

Emerging Healthcare Solutions, Inc.. Unlike other industries, spending on healthcare showed no signs of slowing down and the sector made its biggest one-year jump ever according to a new study by The Centers for Medicare and Medicaid Services (CMS).

17 Feb 2010

Quintiles' anatomic pathology services now available in China to help develop effective cancer treatments

Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to help customers comply with China’s restrictions on tissue import/export.

17 Feb 2010

New research report on orthopedic biomaterials market in the U.S.

According to a new global report series by iData Research (www.idataresearch.net), the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for orthopedic biomaterials grew by 11.5% in 2009 and is estimated to reach almost $6.3 billion by 2016.

17 Feb 2010

New DNA: Dynamic NextGen Analytics platform now available from IntegriChain

IntegriChain, Inc., a commercial insight provider supporting the pharmaceutical industry, announces the launch of its new DNA: Dynamic NextGen Analytics™ (DNA) platform.

17 Feb 2010

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today that the US FDA has granted orphan drug designation for QPI-1002 (also referred to as "I5NP"), a synthetic siRNA targeting p53 mRNA for the prophylaxis of delayed graft function (DGF) in kidney transplant patients.

17 Feb 2010

Embera NeuroTherapeutics establishes clinical development partnership for its cocaine dependence program

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for drug dependence, smoking cessation and obesity, announced today that the company has retained Exponential Pharma Ventures LLC to assist in establishing a clinical development partnership for its cocaine dependence program with a fully integrated pharmaceutical company.

17 Feb 2010

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Celldex Therapeutics, Inc. today announced that it has received a sublicense income payment of $3 million from TopoTarget A/S as a result of the recent co-development and commercialization agreement between TopoTarget and Spectrum Pharmaceuticals, Inc. for Belinostat, a novel histone deacetylase (HDAC) inhibitor for the treatment of cancer.

17 Feb 2010

Chemists adopt new approach to optimise enzyme for practical applications

Engineers are unlikely to tinker with the cooling system if they want to increase the size of an engine. Yet chemists at the Max Planck Institute for Coal Research have adopted an approach similar to this in their efforts to optimise an enzyme for practical applications. They

16 Feb 2010

Teva Novopharm announces name change to Teva Canada Limited

Teva Novopharm announced today it is implementing a name change to Teva Canada Limited, which reinforces the company's relationship with its parent, Teva Pharmaceutical Industries Ltd., the world's largest generic pharmaceutical manufacturer.

16 Feb 2010

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2009.

16 Feb 2010

Derycz Scientific reports second-quarter and half-year fiscal 2010 results

Derycz Scientific, a company that is pioneering a fresh way of facilitating the flow of information from content publishers to enterprise customers and their constituents, announced its second quarter and half-year financial results for fiscal year 2010.

16 Feb 2010

Pharmaceuticals News and Research

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

ECR Pharmaceuticals to promote Urocit-K 15mEq tablets to primary care physicians

Study: Researchers use genomics to decode blueprint of Plasmodium falciparum

Covidien's Exalgo NDA: FDA sets new PDUFA action date

Covidien, IAE POLATOM announce agreement to augment supply of Mo 99 to produce Tc 99m

Ironwood Pharmaceuticals' IPO: Underwriters exercise over-allotment option

USPTO issues two new patents for EKR Therapeutics' RTU Cardene I.V. Premixed Injection

AZ&Me Prescription Savings programs help 13% more patients in 2009

APCER PHARMA to demonstrate pharmacovigilance/drug safety and regulatory services at GPhA meeting

CMS study predicts healthcare spending may double by 2019

Quintiles' anatomic pathology services now available in China to help develop effective cancer treatments

New research report on orthopedic biomaterials market in the U.S.

New DNA: Dynamic NextGen Analytics platform now available from IntegriChain

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

Embera NeuroTherapeutics establishes clinical development partnership for its cocaine dependence program

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Chemists adopt new approach to optimise enzyme for practical applications

Teva Novopharm announces name change to Teva Canada Limited

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Derycz Scientific reports second-quarter and half-year fiscal 2010 results

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence